The Trump administration has struck a deal with EMD Serono to lower drug prices as part of a broader initiative to expand coverage and improve affordability for fertility services, officials announced at the White House on Thursday. This agreement marks a significant step in addressing the growing demand for fertility treatments amidst rising healthcare costs.
The administration’s plan encompasses several key components, including the drugmaker’s commitment to reduce drug prices, the introduction of new benefits rules aimed at encouraging employers to provide in vitro fertilization coverage outside traditional health insurance plans, and a Food and Drug Administration priority review voucher for a fertility drug currently unavailable in the U.S. This multifaceted approach highlights the administration’s recognition of fertility treatment as a critical healthcare issue, with potential implications for regulatory practices and market dynamics in the pharmaceutical sector.
Use the database as your supply chain compass →
